transplant eligible patients with multiple myeloma, the carthadex trial

dexamethasone as induction and consolidation in newly diagnosed,
Phase 2 study of carfilzomib, thalidomide, and low-dose

Ruth Wester, Bronno van der Holt, Emelie Asselbergs, Sonja
Zweegman, Marie Jose Kersten, Edo Vellenga, Marinus van Marwijk
Kooy, Okke de Weerdt, Monique Minnema, Sarah Lonergan, Antonio
Palumbo, Henk Lokhorst, Annemiek Broijl, and Pieter Sonneveld

Sonja Zweegman: advisory boards en research funding Janssen, Celgene, Takeda. Marie
Jose Kersten: Honoraria: Novartis, Kite Pharma, Roche, Celgene, Takeda, Mundipharma,
Gilead, BMS, MSD, Amgen. Research funding: Roche, Celgene, Takeda Edo Vellenga: none
Marinus van Marwijk Kooy: none. Okke de Weerdt: none. Monique Minnema:
Advisory board Celgene, Takeda, Janssen, Amgen, BMS, Servier. Research support
Consultancy: Amgen, Novartis, Bristol-Myers Squibb, Genmab A/S, Celgene,
Janssen-Cilag, Takeda, Sanofi Aventis, Merck, Research funding: Amgen, Novartis,
Bristol-Myers Squibb, Genmab A/S, Celgene, Janssen-Cilag, Takeda, Sanofi Aventis,
Merck, Binding Site Henk Lokhorst: none. Annemiek Broijl: Honoraria Celgene, Janssen,
Amgen, BMS Pieter Sonneveld: Research support to institution: Amgen, Celgene,
Janssen, Karyopharm, SkylineDx, Takeda Advisory Boards: Amgen, Celgene, Janssen,
Karyopharm, SkylineDx, Takeda Honoraria: Amgen, Celgene, Janssen, Karyopharm,
Takeda

Contributions: RW and AB wrote the manuscript BH performed data analysis EA and SL
performed research PS supervised the study SW, MK, EV, MMK, OW, MM, AP and HL
delivered data and critically reviewed the manuscript